Cochrane · systematic review · CD012878
Adalimumab for induction of remission in Crohn's disease
Abbass, M, Cepek, J, Parker, CE, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
7
No studies
2
Included studies
NR
No studies 2 · 22.2%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 22.2%Moderate 2 · 22.2%High 3 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
OutcomesAnalysis 1.4 | no estimate extracted | NR | No studies |
Failure to achieve clinical remission | RR 0.85 [0.79, 0.9] | 3 studies · 714 participants | High |
Failure to achieve clinical response (70‐point response) | RR 0.68 [0.59, 0.79] | 3 studies · 714 participants | High |
Failure to achieve clinical response (100‐point response) | RR 0.77 [0.69, 0.86] | 3 studies · 714 participants | High |
Endoscopic response | no estimate extracted | NR | No studies |
Quality of life (QoL) Inflammatory Bowel Disease Questionnaire (IBDQ) (scale: 32 to 224; higher score = better QoL) | no estimate extracted | 3 studies · 714 participants | Moderate Downgraded: imprecision, inconsistency |
Adverse events | RR 0.9 [0.74, 1.09] | 3 studies · 531 participants | Moderate Downgraded: imprecision, inconsistency |
Serious adverse events | RR 0.44 [0.17, 1.15] | 3 studies · 531 participants | Low Downgraded: imprecision, inconsistency |
Withdrawals due to adverse events | RR 0.38 [0.11, 1.3] | 3 studies · 531 participants | Low Downgraded: imprecision, inconsistency |